95%Confidence
0Views
FDASource
2026-04-18Date
Summary
K.C. Pharmaceuticals' sterility assurance failure for multiple eye drop products distributed through major retailers creates significant public health risks. This affects multiple store brands and could lead to widespread product withdrawals across retail pharmacy chains.
Actionable: Immediately remove all affected eye drop products from inventory and notify customers of potential contamination risks.
AI Confidence: 95%
Data Points
firmK.C. Pharmaceuticals, Inc
classificationClass II
statusOngoing
distributionNationwide in the US
productArtificial Tears Sterile Lubricant Eye Drops (polyvinyl alcohol 0.5%, povidone 0.6%), 0.5 FL OZ (15 mL) bottles; a) LEADER, DISTRIBUTED BY CARDINAL HE
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now